QuTEM Collaborates with Boston University to Bring Advanced Quality Control Analysis to American Gene Therapy Developers

Partnership allows US-based gene therapy companies to access QuTEM's premier analytical services and proprietary software locally

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

QuTEM AB, a leading provider of GMP-certified TEM services and nanoparticle quality control analyses, has announced a successful collaboration with the Boston University Cryogenic Electron Microscopy (BU CryoEM) Core Facility. This partnership allows US-based gene therapy developers to access QuTEM's analytical services and proprietary Gridsee software without the logistical complexities of shipping samples internationally.

Why it matters

The collaboration provides immediate, localized support to leading US gene therapy developers, drastically compressing turnaround times by eliminating transatlantic shipping and potential customs delays. It also provides operational redundancy and uninterrupted service for time-sensitive R&D programs.

The details

Through this expanded workflow, clients send their R&D-level Adeno-Associated Virus (AAV) samples directly to the Boston University facility. Operating under QuTEM's standardized procedures, BU CryoEM scientists perform sample preparation and TEM imaging, with the images then securely transferred to QuTEM's Sweden headquarters for analysis using the Gridsee software. This allows clients to accelerate their pipelines locally while maintaining the same high-quality data as if the work was done at QuTEM's primary labs.

  • QuTEM and Boston University announced the successful launch of the collaboration on March 10, 2026.

The players

QuTEM AB

A world-leading provider of GMP-certified TEM-services and quality control analyses of nanoparticles, based in Stockholm, Sweden.

Boston University Cryogenic Electron Microscopy (BU CryoEM) Core Facility

A custom-designed microscope facility located at the Center for Advanced Biomedical Research on the BU Medical Campus, committed to providing exceptional instrumentation, training, and advice for researchers using cryoEM and cryo Electron Tomography.

Josefina Nilsson

CEO at QuTEM AB.

Got photos? Submit your photos here. ›

What they’re saying

“Because the Boston University facility operates the exact same microscopy equipment as our primary laboratories in Stockholm, we eliminate the technical uncertainties typically associated with scaling up. Clients can accelerate their pipelines locally, completely confident that their R&D data will translate seamlessly as they transition to our European facilities for GMP compliance.”

— Josefina Nilsson, CEO

What’s next

Following the success of the initial project, the Boston University satellite lab is fully operational and actively accepting new US clients. QuTEM is now positioned to rapidly expand its support for North American gene therapy developers.

The takeaway

This collaboration allows US-based gene therapy companies to access QuTEM's premier analytical services and proprietary software locally, accelerating their R&D pipelines while maintaining the same high-quality data as if the work was done at QuTEM's primary labs in Sweden.